Feed MRNA
MR

Moderna

MRNA · NASDAQ

$143.97 +4.26% (+$5.88)
1M +123.35%
Market Cap $57.1B
P/E Ratio -
Div. Yield -
ROE 39.21%
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 25.64x
P/B 8.45x
P/E N/A
Growth
0 /100
Declining
Rev. growth 53.13%
Book val. growth 23.24%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 12.57%
Net margin 141.43%
FCF margin 54.89%
Quality
3 /100
Poor
ROIC 39.97%
ROE 39.21%
Asset turnover 0.20x
Debt
69 /100
Low
Debt/Equity 0.19x
Current ratio 2.29x
Int. coverage -122.80x
Stability
50 /100
Moderate
Beta 0.90x
Rev. volatility 12.29%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre MRNA
Online

Despre companie

Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Stéphane Bancel

Employees

4,700

Headquarters

Cambridge

Evenimente viitoare

05 NOV.

Earnings

Upcoming earnings report

52d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.